title: Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.
abstract: OBJECTIVE
  To determine whether visual functions are decreased in children with infantile spasms and vigabatrin-attributed retinal toxicity.
  
  
  METHODS
  Contrast sensitivity and grating acuity were measured by using sweep visual evoked potential (VEP) testing in 42 children with infantile spasms (mean age, 29.23 +/- 18.31 months). All children had been exposed to vigabatrin (VGB) for a minimum of 1 month. These children were divided into retinal toxicity and no toxicity groupings based on 30-Hz flicker amplitude reductions on the full-field electroretinogram. A multivariate analysis of variance (MANOVA) compared visual functions between children with and without retinal toxicity.
  
  
  RESULTS
  The MANOVA showed that visual function was significantly affected by VGB retinal toxicity. Further univariate analysis revealed that grating acuity was significantly reduced in children with toxicity. No differences in contrast sensitivity were found between children with toxicity and those without.
  
  
  CONCLUSIONS
  Reduced visual functions from VGB-attributed retinal toxicity can be detected in children with infantile spasms with the sweep VEP.
authors.affiliation: Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, Canada.
authors.forename: Sivan
authors.initials: S
authors.lastname: Durbin
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mirabella
authors.forename: J Raymond
authors.initials: JR
authors.lastname: Buncic
authors.forename: Carol A
authors.initials: CA
authors.lastname: Westall
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D015350:Contrast Sensitivity / Q000187:drug effects / Q000502:physiology; D005074:Evoked Potentials, Visual; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012160:Retina / Q000187:drug effects* / Q000503:physiopathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D013036:Spasms, Infantile / Q000188:drug therapy* / Q000503:physiopathology; D020888:Vigabatrin / Q000009:adverse effects*; D014786:Vision Disorders / Q000139:chemically induced* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects* / Q000502:physiology
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin